Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNA2 | P20248 | 4/20 | 0.65 |
| ▸ | CDK2 | P24941 | 4/20 | 0.65 |
| ▸ | IGF1R | P08069 | 4/20 | 0.54 |
| ▸ | NTRK1 | P04629 | 5/20 | 0.49 |
| ▸ | GSK3B | P49841 | 2/20 | 0.44 |
| ▸ | AKT1 | P31749 | 1/20 | 0.44 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.44 |
| ▸ | GSK3A | P49840 | 1/20 | 0.44 |
| ▸ | STK4 | Q13043 | 1/20 | 0.44 |
| ▸ | STK3 | Q13188 | 1/20 | 0.44 |
| ▸ | BMPR2 | Q13873 | 1/20 | 0.44 |
| ▸ | STK26 | Q9P289 | 1/20 | 0.44 |
| ▸ | STK24 | Q9Y6E0 | 1/20 | 0.44 |
| ▸ | SRC | P12931 | 1/20 | 0.44 |
| ▸ | NUAK1 | O60285 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12783887 | 0.88 | CCNA2 (0.68) | CCNA2CDK2IGF1RNTRK1NUAK1 | |
| SCHEMBL12784990 | 0.88 | CCNA2 (0.61) | CCNA2CDK2IGF1RNTRK1GSK3B | |
| SCHEMBL12878269 | 0.86 | CCNA2 (0.66) | CCNA2CDK2IGF1RNTRK1NUAK1 | |
| SCHEMBL2069614 | 0.86 | CCNA2 (0.68) | CCNA2CDK2IGF1RNTRK1GSK3B | |
| SCHEMBL12878463 | 0.85 | CCNA2 (0.74) | CCNA2CDK2IGF1RNTRK1 | |
| SCHEMBL1164470 | 0.84 | CCNA2 (0.46) | CCNA2CDK2IGF1RNTRK1GSK3B | |
| SCHEMBL12784885 | 0.82 | CCNA2 (0.64) | CCNA2CDK2IGF1RNTRK1 | |
| SCHEMBL12878583 | 0.82 | CCNA2 (0.68) | CCNA2CDK2IGF1RNTRK1 | |
| SCHEMBL1163675 | 0.82 | IGF1R (0.57) | CCNA2CDK2IGF1RNTRK1GSK3B | |
| SCHEMBL12784422 | 0.82 | CCNA2 (0.63) | CCNA2CDK2IGF1RNTRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9422271-B2 | Pyrimidine compounds as tuberculosis inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2016-08-23 | — | — | US | disclosed |
| US-9422271-B2 | Pyrimidine compounds as tuberculosis inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2016-08-23 | — | — | US | disclosed |
| US-20140249137-A1 | PYRIMIDINE COMPOUNDS AS TUBERCULOSIS INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-09-04 | — | — | US | disclosed |
| US-20140249137-A1 | PYRIMIDINE COMPOUNDS AS TUBERCULOSIS INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-09-04 | — | — | US | disclosed |
| US-20110053916-A1 | PYRIMIDINE COMPOUNDS AS TUBERCULOSIS INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-03-03 | — | — | US | disclosed |
| US-20110053916-A1 | PYRIMIDINE COMPOUNDS AS TUBERCULOSIS INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140249137-A1 | PYRIMIDINE COMPOUNDS AS TUBERCULOSIS INHIBITORS | TYMS, TYMP, DPYD | CCNA2 1047/4885CDK2 122/4885IGF1R 4443/4885 |
| US-20110053916-A1 | PYRIMIDINE COMPOUNDS AS TUBERCULOSIS INHIBITORS | TYMS, TYMP, DPYD | CCNA2 1047/4885CDK2 122/4885IGF1R 4443/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.